Efficient drug delivery of paclitaxel glycoside: A novel solubility gradient encapsulation into liposomes coupled with immunoliposomes preparation

PLoS ONE

Volumn 9, Issue 9, 2014, Pages

  Shigehiro, Tsukasa ^a   Kasai, Tomonari ^a   Murakami, Masaharu ^a   Sekhar, Sreeja C ^a   Tominaga, Yuki ^a   Okada, Masashi ^a   Kudoh, Takayuki ^a   Mizutani, Akifumi ^a   Murakami, Hiroshi ^a   Salomon, David S ^b   Mikuni, Katsuhiko ^c   Mandai, Tadakatsu ^d   Hamada, Hiroki ^e   Seno, Masaharu ^a  

^a OKAYAMA UNIVERSITY   (Japan)

^b NATIONAL CANCER INSTITUTE   (United States)

^c Ensuiko Sugar Refining Co Ltd   (Japan)

^d KURASHIKI UNIVERSITY OF SCIENCE AND THE ARTS   (Japan)

^e OKAYAMA UNIVERSITY OF SCIENCE   (Japan)

Author keywords

[No Author keywords available]

Indexed keywords

7 GLUCOSYLOXYACETYLPACLITAXEL; ALCOHOL; CREMOPHOR; EPIDERMAL GROWTH FACTOR RECEPTOR 2; ETHYLENE GLYCOL; IMMUNOLIPOSOME; LIPOSOME; PACLITAXEL DERIVATIVE; TRASTUZUMAB; UNCLASSIFIED DRUG; DRUG CARRIER; GLYCOSIDE; PACLITAXEL;

ACUTE TOXICITY; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CANCER CELL; CANCER INHIBITION; COLON CANCER; CONJUGATION; CONTROLLED STUDY; DRUG CYTOTOXICITY; DRUG EFFICACY; DRUG FORMULATION; DRUG SOLUBILITY; ENCAPSULATION; FEMALE; HUMAN; HUMAN CELL; HYDROPHILICITY; IN VITRO STUDY; IN VIVO STUDY; MICROTUBULE ASSEMBLY; MOUSE; NONHUMAN; TUMOR XENOGRAFT; ANIMAL; BAGG ALBINO MOUSE; CHEMISTRY; HT 29 CELL LINE; SOLUBILITY;

MUS; MUS MUSCULUS;

ANIMALS; DRUG CARRIERS; FEMALE; GLYCOSIDES; HT29 CELLS; HUMANS; LIPOSOMES; MICE; MICE, INBRED BALB C; PACLITAXEL; SOLUBILITY;

EID: 84907485962     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0107976     Document Type: Article

References (33)

1. Singla AK, Garg A, Aggarwal D (2002) Paclitaxel and its formulations. Int J Pharm 235: 179-192.
2. Pazdur R, Kudelka AP, Kavanagh JJ, Cohen PR, Raber MN (1993) The taxoids: paclitaxel (Taxol) and docetaxel (Taxotere). Cancer Treat Rev 19: 351-386.
3. Gelderblom H, Verweij J, Nooter K, Sparreboom A (2001) Cremophor EL: the drawbacks and advantages of vehicle selection for drug formulation. Eur-J Cancer 37: 1590-1598.
4. Ma P, Mumper RJ (2013) Paclitaxel Nano-Delivery Systems: A Comprehensive Review. J Nanomed Nanotechnol 4: 1000164.
5. Maruyama K (2011) Intracellular targeting delivery of liposomal drugs to solid tumors based on EPR effects. Adv Drug Deliv Rev 63: 161-169.
6. Allen TM, Cullis PR (2013) Liposomal drug delivery systems: from concept to clinical applications. Adv Drug Deliv Rev 65: 36-48.
7. Rusnak DW, Alligood KJ, Mullin RJ, Spehar GM, Arenas-Elliott C, et al. (2007) Assessment of epidermal growth factor receptor (EGFR, ErbB1) and HER2 (ErbB2) protein expression levels and response to lapatinib (Tykerb, GW572016) in an expanded panel of human normal and tumour cell lines. Cell Prolif 40: 580-594.
8. Tai W, Mahato R, Cheng K (2010) The role of HER2 in cancer therapy and targeted drug delivery. J Control Release 146: 264-275.
9. Park JW, Hong K, Kirpotin DB, Meyer O, Papahadjopoulos D, et al. (1997) Anti-HER2 immunoliposomes for targeted therapy of human tumors. Cancer Lett 118: 153-160.
10. Park JW, Kirpotin DB, Hong K, Shalaby R, Shao Y, et al. (2001) Tumor targeting using anti-her2 immunoliposomes. J Control Release 74: 95-113.
11. Park JW, Hong K, Kirpotin DB, Colbern G, Shalaby R, et al. (2002) Anti-HER2 immunoliposomes: enhanced efficacy attributable to targeted delivery. Clin Cancer Res 8: 1172-1181.
12. Yang T, Choi MK, Cui FD, Lee SJ, Chung SJ, et al. (2007) Antitumor effect of paclitaxel-loaded PEGylated immunoliposomes against human breast cancer cells. Pharm Res 24: 2402-2411.
13. Crosasso P, Ceruti M, Brusa P, Arpicco S, Dosio F, et al. (2000) Preparation, characterization and properties of sterically stabilized paclitaxel-containing liposomes. J Control Release 63: 19-30.
14. Yang T, Choi MK, Cui FD, Kim JS, Chung SJ, et al. (2007) Preparation and evaluation of paclitaxel-loaded PEGylated immunoliposome. Journal of Controlled Release 120: 169-177.
15. Koudelka S, Turánek-Knötigová P, Masek J, Korvasová Z, Skrabalová M, et al. (2010) Liposomes with high encapsulation capacity for paclitaxel: Preparation, characterisation and in vivo anticancer effect. J Pharm Sci 99: 2309-2319.
16. Kan P, Tsao CW, Wang AJ, Su WC, Liang HF (2011) A liposomal formulation able to incorporate a high content of Paclitaxel and exert promising anticancer effect. J Drug Deliv 2011: 629234.
17. Koudelka S, Turánek J (2012) Liposomal paclitaxel formulations. J Control Release 163: 322-334.
18. Barenholz Y (2012) Doxil-the first FDA-approved nano-drug: lessons learned. J Control Release 160: 117-134.
19. Mandai T, Okumoto H, Oshitari T, Nakanishi K, Mikuni K, et al. (2001) Synthesis and biological evaluation of water soluble taxoids bearing sugar moieties. Heterocycles 54: 561-566.
20. Gao J, Liu W, Xia Y, Li W, Sun J, et al. (2011) The promotion of siRNA delivery to breast cancer overexpressing epidermal growth factor receptor through anti-EGFR antibody conjugation by immunoliposomes. Biomaterials 32: 3459-3470.
21. Steinhauser I, Spänkuch B, Strebhardt K, Langer K (2006) Trastuzumab-modified nanoparticles: optimisation of preparation and uptake in cancer cells. Biomaterials 27: 4975-4983.
22. Xu H, Yu Y, Marciniak D, Rishi AK, Sarkar FH, et al. (2005) Epidermal growth factor receptor (EGFR)-related protein inhibits multiple members of the EGFR family in colon and breast cancer cells. Mol Cancer Ther 4: 435-442.
23. Zhigaltsev IV, Winters G, Srinivasulu M, Crawford J, Wong M, et al. (2010) Development of a weak-base docetaxel derivative that can be loaded into lipid nanoparticles. J Control Release 144: 332-340.
24. Vaidyanath A, Hashizume T, Nagaoka T, Takeyasu N, Satoh H, et al. (2011) Enhanced internalization of ErbB2 in SK-BR-3 cells with multivalent forms of an artificial ligand. J Cell Mol Med 15: 2525-2538.
25. Sharma A, Mayhew E, Bolcsak L, Cavanaugh C, Harmon P, et al. (1997) Activity of paclitaxel liposome formulations against human ovarian tumor xenografts. Int J Cancer 71: 103-107.
26. Yoshizawa Y, Kono Y, Ogawara K, Kimura T, Higaki K (2011) PEG liposomalization of paclitaxel improved its in vivo disposition and anti-tumor efficacy. Int J Pharm 412: 132-141.
27. Yang T, Cui FD, Choi MK, Cho JW, Chung SJ, et al. (2007) Enhanced solubility and stability of PEGylated liposomal paclitaxel: in vitro and in vivo evaluation. Int J Pharm 338: 317-326.
28. Fetterly GJ, Straubinger RM (2003) Pharmacokinetics of paclitaxel-containing liposomes in rats. AAPS PharmSci 5: E32.
29. Sparreboom A, van Asperen J, Mayer U, Schinkel AH, Smit JW, et al. (1997) Limited oral bioavailability and active epithelial excretion of paclitaxel (Taxol) caused by P-glycoprotein in the intestine. Proc Natl Acad Sci USA 94: 2031-2035.
30. Spratlin J, Sawyer MB (2007) Pharmacogenetics of paclitaxel metabolism. Crit Rev Oncol Hematol 61: 222-229.
31. Kirpotin DB, Drummond DC, Shao Y, Shalaby MR, Hong K, et al. (2006) Antibody targeting of long-circulating lipidic nanoparticles does not increase tumor localization but does increase internalization in animal models. Cancer Res 66: 6732-6740.
32. Desai N, Trieu V, Yao Z, Louie L, Ci S, et al. (2006) Increased antitumor activity, intratumor paclitaxel concentrations, and endothelial cell transport of cremophor-free, albumin-bound paclitaxel, ABI-007, compared with cremo-phor-based paclitaxel. Clin Cancer Res 12: 1317-1324.
33. Wang H, Cheng G, Du Y, Ye L, Chen W, et al. (2013) Hypersensitivity reaction studies of a polyethoxylated castor oil-free, liposome-based alternative paclitaxel formulation. Mol Med Rep 7: 947-952.